Author/Authors :
Stepanova, L.A. Research Institute of Influenza, russia , Sergeeva, M.V. Research Institute of Influenza, russia , Shuklina, M.A. Research Institute of Influenza, russia , Shaldzhyan, A.A. Research Institute of Influenza, russia , Potapchuk, M.V. Research Institute of Influenza, russia , Korotkov, A.V. Research Institute of Influenza, russia , Tsybalova, L.M. Research Institute of Influenza, russia
Abstract :
Conserved fragments of the second subunit of hemagglutinin (HA2) are of great interest for the design of vaccine constructs that can provide protective immunity against influenza A viruses of different sub-types. A recombinant fusion protein, FlgMH, was constructed on the basis of flagellin and a highly conserved HA2 fragment (35–107) of influenza viruses of the subtype A/H2N2, containing B cell, CD4+ T cell, and CD8+ T cell epitopes. The native conformation of the HA2 fragment was partially preserved upon its attachment to the C-terminus of flagellin within the recombinant fusion protein FlgMH. FlgMH was shown to stimulate a mixed Th1/Th2 response of cross-reactive antibodies, which bind to influenza viruses of the first phylogenetic group (H1, H2, H5), to the target sequence as well as the induction of specific cytotoxic T cells (CD3+CD8+IFNγ+). Immunization with the recombinant protein protected animals from a lethal influenza infection. The developed FlgMH protein is a promising agent that may be included in an influenza vaccine with a wide spectrum of action which will be able to stimulate the T and B cell immune responses.
Keywords :
vaccine , influenza , HA2 , recombinant protein , flagellin